Celgene Corporation (CELG): Expanding Labels to Expand Margins

Page 1 of 2

In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company’s financial health. Is cash being applied efficiently to maximize sales while minimizing the cost of R&D? Perhaps the most powerful way to maximize revenue potential and minimize cost is through label expansion.

Companies with nascent revenue streams must appropriately limit costs while fostering newfound revenue. By selectively searching for new indications, or approved uses, for drugs, pharma can bypass the costly process of novel drug discovery, enhance manufacturing and commercialization margins by extending the utility of fixed costs, and grow revenue by exposing the drug to patients in new markets. The industry is teeming with drugs for which companies have cut margins by expanding drug labels.

Below we will look at a few exemplary cases in which label expansion has improved the growth prospects of drugmakers in two sectors.

Oncology

The oncology space provides biotech or pharmaceutical companies with a great opportunity to expand labels. FDA approval for cancer drugs can be specific to cancer type and treatment regimen (primary treatment vs secondary or co-treatment). Yet the diversity of cancer types with common molecular underpinnings makes some drugs widely applicable, providing an opportunity to expand the market without the costs of complete drug development.

Celgene Corporation (NASDAQ:CELG)Celgene Corporation (NASDAQ:CELG) is a wonderful example of a company pursuing label expansion. Celgene has six approved drugs on the market for treatment of cancer. Of those six, five of them are in additional clinical trials or are under FDA review for use in new indications. Eleven Phase III trials are currently listed on Celgene’s website, investigating the use of approved drugs in additional indications. Contrast this with the four Phase III trials underway for new drug candidates, and it is clear that Celgene’s short-term revenue growth will come from label expansion, providing ample capital to be invested in preclinical drug discovery.

Celgene Corporation (NASDAQ:CELG)’s leading revenue generator, Revlimid, is currently approved to treat two types of blood cancer – including as a secondary treatment multiple myeloma and relapsing or treatment-resistant mantle cell lymphoma – and for diseases of the bone marrow called myelodysplastic syndromes. Revlimid brought in $3.7 billion in 2012, yet Celgene continues to exploit the drug’s widespread utility with clinical trials for twelve additional indications (eight are in Phase III). The recent success of Revlimid as a primary treatment for multiple myeloma in a Phase III trial suggests that this strategy might pay off, sending the stock to new all-time highs.

Celgene Corporation (NASDAQ:CELG)’s multiple myeloma competitor Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is another example of a company using label expansion to limit costs. While annual operating expenses did increase from 2011 to 2012, Onyx’s 10-K suggests that this is in large part due to costs incurred from label expansion of its only wholly owned drug, Kyprolis. Kyprolis was approved in 2013 as a third-line treatment for multiple myeloma. It is now in three additional Phase 3 trials for other multiple myeloma treatment courses. Amgen, Inc. (NASDAQ:AMGN)‘s rumored $10 billion acquisition offer to Onyx suggests that they, too, appreciate Onyx’ commitment to label expansion. Onyx has rebuffed that offer, but it will certainly be interesting to see which suitor also values Onyx’ approach to drug development.

Autoimmune Disease

Like cancer, autoimmune disorders come in many varieties and flavors, yet often times the underlying molecular causes are similar enough that one drug can treat myriad illnesses. This is particularly the case for diseases of chronic inflammation.

A specific chemical pathway in most cells called the Tumor Necrosis Factor, or TNF, pathway can be activated by the immune system to cause ‘programmed’ cell death. In healthy subjects, this pathway helps to keep potentially dangerous tumor cells from spreading. In other cases, hyperactivity of the pathway can cause inflammation and tissue damage, among other things. This pathway can therefore be blocked to treat diverse ailments associated with auto-immune diseases and inflammation. Four companies have cashed in big time with blockbuster drugs targeting TNF signaling.

AbbVie’s Humira, Amgen, Inc. (NASDAQ:AMGN)‘s and Pfizer Inc. (NYSE:PFE)’s Enbrel, and Johnson & Johnson (NYSE:JNJ)’s Remicade combined for $23 billion in 2012. Treating diseases as diverse as rheumatoid arthritis, to Crohn’s Disease, to psoriasis, these drugs have thrived in large part because of their expansive labels. AbbVie is currently pursuing five additional indications (in the US) for further label expansion of Humira – currently the best selling drug in the world.

Drug 2012 Revenue
Approved Indications*
Humira $9.27 billion 7
Enbrel $7.97 billion 5
Remicade $6.14 billion 8

Source: Full Prescribing Information on drug website. Only in US.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!